Abbott Laboratories $ABT Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 27.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 13,023 shares of the healthcare product maker’s stock after selling 4,807 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Abbott Laboratories were worth $1,744,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABT. IMG Wealth Management Inc. lifted its holdings in Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares during the period. Anfield Capital Management LLC increased its holdings in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at $32,000. Copia Wealth Management purchased a new stake in Abbott Laboratories during the third quarter worth $38,000. Finally, Curio Wealth LLC grew its position in Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock valued at $42,000 after buying an additional 305 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on ABT. Weiss Ratings reissued a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday. Barclays raised their price objective on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Piper Sandler reduced their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $140.79.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s chairman, Robert B. Ford, bought $2 million of ABT stock — an insider buy that signals management confidence. Chairman Buys $2M in ABT
• Positive Sentiment: Evercore ISI reiterated an Outperform rating and said Abbott’s core growth drivers remain intact despite trimming its price target to $138 — supportive analyst view even after the quarter. Evercore: Core Growth Drivers Intact
• Positive Sentiment: Market momentum: Abbott snapped six straight sessions of losses, which can attract short‑covering and momentum buyers. ABT Snaps Losing Streak
• Positive Sentiment: Bullish analysis: At least one analyst piece highlights double‑digit earnings growth potential, reinforcing longer‑term upside narratives. Double‑Digit Earnings Growth Thesis
• Neutral Sentiment: Stock is a trending/searched ticker on retail platforms, drawing attention from momentum traders and retail buyers. Zacks: Trending Stock
• Neutral Sentiment: Commentary pieces ask whether January’s pullback is a buying opportunity, keeping ABT in retail and advisor conversations. Is the Pullback a Buy?
• Neutral Sentiment: Roundups of hedge‑fund and insider activity mention ABT among other names — informational but not clearly directional. Hedge Fund & Insider News
• Negative Sentiment: Multiple sell‑side firms trimmed price targets or issued cautious/pessimistic forecasts after the quarter (reduced revenue vs. expectations and cautious guidance). Notable items include cuts/negative notes from Royal Bank of Canada, Citigroup, Goldman Sachs, Sanford C. Bernstein and others — a headwind for near‑term sentiment. RBC Lowers PT to $135 Citigroup Pessimistic Forecast Goldman Sachs Negative Note

Abbott Laboratories Stock Performance

NYSE ABT opened at $108.79 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The stock’s 50 day simple moving average is $124.34 and its 200-day simple moving average is $128.12. The company has a market cap of $189.18 billion, a PE ratio of 29.25, a price-to-earnings-growth ratio of 1.78 and a beta of 0.72. Abbott Laboratories has a 1-year low of $105.78 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the prior year, the company earned $1.34 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.